Brainstorm Cell Therapeutics Stock Set to Reverse Split on Tuesday, October 1st (NASDAQ:BCLI)

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s stock is set to reverse split on the morning of Tuesday, October 1st. The 1-15 reverse split was announced on Thursday, September 26th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, September 30th.

Brainstorm Cell Therapeutics Trading Down 12.6 %

Brainstorm Cell Therapeutics stock opened at $0.22 on Friday. Brainstorm Cell Therapeutics has a 12-month low of $0.13 and a 12-month high of $0.79. The stock has a market cap of $15.59 million, a P/E ratio of -0.70 and a beta of 0.35. The company has a 50-day moving average price of $0.30 and a 200 day moving average price of $0.41.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). During the same quarter last year, the firm earned ($0.27) EPS. As a group, analysts forecast that Brainstorm Cell Therapeutics will post -0.19 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on BCLI. Maxim Group upgraded shares of Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research report on Thursday, July 11th. StockNews.com began coverage on shares of Brainstorm Cell Therapeutics in a research report on Monday, September 23rd. They set a “hold” rating for the company.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC bought a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned 0.12% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. Institutional investors own 14.33% of the company’s stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.